CNPLE prescribing and pharmacology questions for Canadian NPs

Canadian NPs hold independent prescriptive authority within their legislated scope — the breadth of which varies by province and territory but generally includes a wide formulary for primary care, mental health, women's health, paediatrics, and chronic disease management. Unlike registered nurses, NPs do not require physician co-signature to prescribe within their scope. This independent authority is central to the CNPLE's prescribing safety emphasis.

CNPLE prescribing questions test this authority directly. Scenarios present a patient with a new diagnosis or an ongoing condition requiring medication adjustment, and ask the NP to select the most appropriate pharmacological management — accounting for comorbidities, drug interactions, and patient-specific factors like renal function, hepatic status, pregnancy, age, and adherence context.

Cardiovascular pharmacology is consistently high yield: antihypertensive selection (ACE inhibitors vs. ARBs vs. CCBs vs. thiazides, with specific contraindications), anticoagulation initiation and monitoring (warfarin vs. DOACs), statin prescribing and safety, and heart failure pharmacotherapy. Candidates who understand the rationale behind drug selection — not just the drug name — perform significantly better on integrated CNPLE-style scenarios.

Mental health pharmacology is equally essential: antidepressant selection (SSRIs, SNRIs, bupropion, mirtazapine), SSRI titration and discontinuation syndrome, antipsychotic adverse effect profiles, lithium monitoring, and benzodiazepine prescribing safety. Women's health pharmacology — contraception selection, hormone therapy initiation and contraindications, and pregnancy-safe prescribing — is another reliable CNPLE domain.

Special population prescribing is tested through every domain: dose adjustments in renal impairment, hepatic dysfunction, older adults (Beers Criteria, polypharmacy risk), and pregnancy. Understanding how a first-line drug changes — or becomes contraindicated — in the presence of a comorbidity is the clinical reasoning the CNPLE rewards.

Drug–drug interactions appear in CNPLE prescribing scenarios because real NP practice requires scanning the medication list before adding a new agent. Key interaction patterns include: CYP450-mediated interactions (clarithromycin + statins, warfarin + multiple agents), QTc-prolonging combinations, serotonin syndrome risk with dual serotoninergic prescribing, and nephrotoxicity with combined NSAID/ACE inhibitor/diuretic use.

The clinical format is usually: a patient on two or three existing medications presents with a new condition requiring pharmacotherapy. The NP must select an appropriate agent that does not create a dangerous interaction, adjusting for comorbidities and monitoring needs. Practice with this integrated format prevents the common error of answering based on a single condition in isolation.

Prescribing safety on the CNPLE extends beyond drug selection to ongoing management: when to check drug levels (lithium, digoxin, vancomycin), what lab monitoring a new prescription requires (renal function with ACE inhibitors, LFTs with statins, CBC with methotrexate), and which adverse effects require immediate discontinuation versus watchful management.

Follow-up prescribing decisions are also tested: a patient prescribed an antihypertensive returns with an inadequate response. The CNPLE-aligned question asks whether to increase the dose, add a second agent, switch to a different class, or investigate for secondary hypertension. The answer depends on baseline values, adherence, adverse effects, and the clinical picture — precisely the integrated reasoning prescribing practice builds.